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Abstract The Belgian Neuromuscular Disease Registry,
commissioned in 2008, aims to collect data to improve
knowledge on neuromuscular diseases and enhance quality
health services for neuromuscular disease patients. This
paper presents a clear outline of the strategy to launch a
global national registry. All patients diagnosed with one of
the predefined 62 neuromuscular disease groups and living
in Belgium may be included in the yearly updated Registry.
Basic core data is harvested through a newly designed web
application by the six accredited neuromuscular reference
centres. In 2010, 3,424 patients with a neuromuscular
disorder were registered. The most prevalent disease group
in the Registry is Hereditary Motor and Sensory Neurop-
athy, as similarly stated by other studies, albeit the preva-
lence in Belgium is five times lower: 6.5 per 100,000 in the
north of Belgium, versus 17.0–41.0 per 100,000 in other
areas of Europe. Very few patients were captured in the
south of the country. With the aim to collect valuable
epidemiological data, the registry targets to gather high
quality data, that the sample to be representative of the
population and that it be complete. The past 5 years of
building the registry have improved its quality, albeit the
consistent gap in data from the south of the country pre-
vails, influencing the estimated prevalence of these dis-
eases. To this day, the true burden of neuromuscular
diseases in Belgium is not known but actions have been
undertaken to address these issues.
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Introduction
On average, 6,000 rare diseases have been identified,
affecting 6–8 % of the overall population [1]. In Europe,
this would mean that there are 27–36 million people living
with these isolated diseases. Tackling rare diseases is high
on the European political agenda as stated in the 7th
framework programme from 2007 to 2013 [1–3].
The term neuromuscular diseases encompasses condi-
tions impacting the neuromuscular system, including the
motor neurons, other spinal cord regions, the peripheral
nerves, to the neuromuscular junction and the muscle.
These diseases are rare, often hereditary, progressive in
nature and without treatment. Some of these can be of
autoimmune origin and treatable. The onset of symptoms
ranges from childhood to adulthood and may vary from
mild to more severe sensory and/or motor impairment,
sometimes cardiac or respiratory involvement requiring life
support and/or resulting in fatality. According to Orphanet,
European portal for rare diseases and orphan drugs, the
threshold of a rare disease is less than a person per 2,000
[4]. In contrast to the low frequency, neuromuscular dis-
eases have a great impact on the quality of life of the
patients, underlining the importance of a rapid diagnosis to
guide the patient towards the most appropriate therapies.
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According to the World Health Organisation, a patient
registry is ‘‘a file of documents containing uniform infor-
mation about individual persons, collected in a systematic
and comprehensive way, in order to serve a pre-determined
scientific, clinical or policy purpose’’ [5]. For the purpose
of this article, a global registry was defined as a registry
focusing on a group of related diseases. With this intention,
the Belgian Neuromuscular Disease Registry (BNMDR)
was created in 2008. Its goals are to increase the epide-
miological knowledge of these diseases, to promote health
services for patients having these diseases, to recruit
patients for clinical trials and to provide information to the
public health authorities for planning of health care in
Belgium. It is a global registry collecting data on 62 dif-
ferent neuromuscular disease groups, highlighting the
evolution of the diseases and monitoring their estimated
prevalence throughout time in Belgium. To date, global
neuromuscular disease registries are scarce, existing only
in Canada [6], Australia [7], New Zealand [8], The Neth-
erlands [9], and Belgium. However, most industrialised
countries have certain rare disease-specific registries,
independent of each other [10]. A global registry contrasts
with disease-specific registries as it is time and resource
saving in the preparation of tools and analysis of the data as
the expertise is centralized. As each rare disease affects
relatively small numbers of patients, grouping them
enables further statistical analysis.
In this article we describe the methods used to build a
rare disease registry and we carried out the first evaluation
on the representativeness and exhaustiveness of the regis-
try. For epidemiological purposes, the registry targets three
aims: to collect data of high quality, have a representative
sample and as ultimate goal to include the entire target
population for completeness.
Methods
Organization and leadership
The registry began in 2008. Through agreements, it collects
data by six Neuromuscular Reference Centres (NMRC)
which is then analysed by the Scientific Institute of Public
Health (WIV-ISP). It is funded by the National Insurance
of Health and Disability Institute of Belgium (NIHDI)
financing each NMRC per patient registered. A NMRC is a
centre that has signed a convention with the NIHDI for
health services for patients with neuromuscular diseases
and provides a multi-disciplinary approach for those
patients. There are two NMRCs in Brussels, three in
Flanders, the northern part of Belgium, and one in Wal-
lonia, the south. Patients, having been diagnosed with a
neuromuscular disease, are seen in a NMRC of their
choice, signing a yearly renewed convention. The leader-
ship of the registry is carried out by the steering committee,
composed of representatives from the NIHDI, WIV-ISP
and experts from each NMRC. A national legal and consent
framework was established to bind the partners in the
project. Simultaneously a request for secondary use of data
from patient health records was sent to the privacy com-
mission of the sectorial health committee dealing with data
protection issues and privacy enhancing techniques. The
study protocol was accepted by the Commission d’Ethique
Biome´dicale Hospitalo-Facultaire of the Universite´ Cath-
olique de Louvain. After which, they contacted the five
other medical ethics committees at the university hospitals
harbouring each NMRC.
There is close collaboration with the eHealth platform, a
Belgian public institution whose mission is to support
patient information exchange between healthcare profes-
sionals. They ensure the respect of the privacy rights and
patient confidentiality. Their aim is to optimize continuous
care, patient security, simplify administrative steps and to
offer support for health care politics [11]. The eHealth
platform services also provide a third party coding to
generate a unique identification number per patient based
on the National Social Security Number, thus maintaining
the patient’s anonymity.
The registry also gathers data for Translational Research
in Europe for the Assessment and Treatment of Neuro-
muscular Diseases (TREAT-NMD), which is an European
network providing the infrastructure and registry-building
tools to professionals since 2007 [12]. The genetic muta-
tion and detailed clinical data is gathered for Duchenne
Muscular Dystrophy and Spinal Muscular Atrophy. In
addition to facilitating the creation of registries, TREAT-
NMD maintains an updated list of disease-specific regis-
tries Europe-wide for participants’ networking purposes.
Study population
All patients followed in a NMRC, diagnosed with one of
the determined 62 neuromuscular disease groups (Table 1)
and living in Belgium can be included in the registry. Each
patient has signed an informed consent form.
Data collection
The data collected originates from health records, gathered
manually on a yearly basis by the centres. The basic core
data collected covers socio-demographic information such
as gender, age, and residence of the patients at district
level, as well as the diagnosis and the evolution of their
disease.
The diagnostic classification was recently updated by
the experts for the 2010 data collection, altering the
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previous list of 47–62 neuromuscular disease groups. It
was carried out to update the classification according to the
research evolution (Table 1).
The 2010 cross-sectional data collection was carried out
from 4 June 2011 to 14 January 2012. This article will
focus on this data collection.
Data collection tool
Throughout time, different tools were created for the data
collection in the BNMDR. The first tool was an ACCESS-
based application (version 0) which was installed locally
on each computer of every NMRC. Due to local patient
coding, this application did not permit to identify patients
who had been seen at more than one centre, thus possibly
including double entries in the database. It was also not
conceived to ensure proper patient privacy.
The second tool was a web-based application (version
1), used for the 2010 data collection, accessible online with
a secured code for the professional entering the data and
equipped with central patient coding. To identify double
entries, each patient was given a unique identifier code kept
throughout time. This BNMDR identifier was defined by
the services of the eHealth platform, functioning as a
Trusted Third Party, by re-coding the unique National
Social Security Number of the patient, thus allowing lon-
gitudinal research.
Data management and plan of statistical analysis
After the data collection, error checking routines were
carried out for range and consistency especially to identify
in a unique way the double patient entries from patients
Table 1 Neuromuscular disease classification, BNMDR 2013
Muscular dystrophies Disorder of the motor neurons
1 Congenital muscular
dystrophy
35 Amyotrophic lateral sclerosis
2 Duchenne muscular
dystrophy
36 Primary muscular atrophy
3 Becker muscular
dystrophy
37 Postpolio syndrome
4 Dystrophinopathy 38 Primary lateral sclerosis
5 Facioscapulohumeral
dystrophy
39 Werdnig-Hoffman spinal
muscular atrophy
6 Limb girdle muscular
dystrophy
40 Intermediate spinal muscular
atrophy
7 Emery-Dreifuss
muscular dystrophy
41 Kugelberg–Welander spinal
muscular atrophy
8 Distal myopathy 42 Adult spinal muscular atrophy
9 Oculopharyngeal
muscular dystrophy
43 X-linked Bulbo-spinal
muscular atrophy or
Kennedy‘s disease
10 Myotonic dystrophy
type 1
44 Distal spinal muscular
atrophy
11 Myotonic dystrophy
type 2
45 Hereditary spastic paraplegia
12 Other muscular
dystrophies
46 Other disorders of motor
neurons
Myotonic and relaxation
disorders
Neuropathies
13 Thomsen type
myotonia congenita
Hereditary
14 Becker type myotonia
congenita
47 Hereditary motor and sensory
neuropathy
15 Paramyotonia
congenita
48 Hereditary neuropathy with
liability to pressure palsies
16 Familial periodic
paralysis
49 Hereditary sensory and
autonomous neuropathy
17 Other myotonic
disorders
Inflammatory
Myopathies 50 Guillain-Barre´ syndrome
Congenital myopathies 51 Chronic inflammatory
demyelinating
polyneuropathy
18 Central core disease 52 Multifocal motor neuropathy
19 Multiminicore
disease
53 Vasculitis
20 Nemaline myopathy 54 Neuropathy associated with
paraproteinemia
21 Myotubular
myopathy
55 Neuropathy associated with
plasma cell dyscrasia
22 Centronuclear
myopathy
56 Amyloidosis
23 Fibre type
disproportion
myopathy
57 Neuropathy in systemic
disease
Metabolic myopathies 58 Other neuropathies
24 Muscle glycogenosis Hereditary ataxias
25 Disorders of fatty
acid metabolism
59 Friedreich ataxia
Table 1 continued
26 Mitochondrial myopathy 60 Spinocerebellar
ataxias
Inflammatory myopathies 61 Other Hereditary
ataxias
27 Polymyositis Various
28 Dermatomyositis 62 Arthrogryposis
multiplex congenita
29 Inclusion body myositis
Other myopathies
30 Other myopathies
Disorder of the neuromuscular
transmission
31 Myasthenia gravis
32 Congenital myasthenia
33 Lambert-Eaton syndrome
34 Other disorders of
neuromuscular transmission
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having attended two different centres. Six of the 39 patients
(n = 3,424) having been seen by two different centres had
different diagnoses and were discarded. For the remaining
33 patients having a double entry, the first entry was
retained as both diagnoses were the same.
Considering that the continuous variables were not
normally distributed, the median was used, with confidence
interval at 95 % (CI 95 %).
The prevalence was estimated and used as an indicator
to evaluate the completeness of the registry knowing that it
only represents an ‘‘estimated prevalence’’. It was calcu-
lated as a quotient between the number of cases in the
registry over the total population at the same time period,
as a rate. The 95 % CI was calculated according to Poisson
distribution. The total population living in Belgium, was
calculated at mid-year, derived from an average based on
the total population on the 1st of January 2010 and 1st of
January 2011. Considering that Duchenne Muscular Dys-
trophy is X-linked, the denominator for that disease was
based only on the male mid-population. For the estimated
prevalence of the regions, the values used came from the
1st of January 2010, as there was no available data from
2011 [13, 14].
The descriptive statistical analysis was done with Stata
10.
Results
The present study of 2010 was based on 3,424 patients
with neuromuscular diseases. The overall registry popu-
lation was composed of 56.1 % men and 43.9 % women.
The median age was 46.0 years (CI 95 %
45.0–47.0 years). The median age of the first symptoms
was known for 28.8 % of the patients and was 30.0 years
(CI 95 % 25.0–33.0 years). The median age of diagnosis
was known for 51.8 % of the patients and was 38.0 years
old (CI 9 % 36.0–39.0 years). The time lapse between the
first symptoms and diagnosis age was shown to be
2.1 years (CI 95 % 1.8–2.6) for 18.2 % of the patients
(n = 622). The stage of disease was divided in four cat-
egories, 2.1 % were at the diagnosis stage where symp-
toms could not be observed, 69.3 % had symptoms but
were still mobile, 26.0 % were wheelchair dependent and
2.6 % on life support. In 2010, 117 patients died, of those,
75 had amyotrophic lateral sclerosis.
An estimated prevalence of the nine most frequent dis-
eases in BNMDR per 100,000 inhabitants can be found in
Table 2. The prevalence of only three diseases in BNMDR
are included in the literature prevalence range, Myotonic
Dystrophy type 1, Spinocerebellar Ataxias, and Chronic
Inflammatory Demyelinating Polyneuropathy whereas the
other six have lower estimated prevalence compared to the
literature values. Figure 1 is a map displaying the preva-
lence of the diseases per 100,000 inhabitants and by the 43
Belgian districts. Considerable differences can be noticed
between the northern and the southern parts of the country.
Tables 2 and 3 illustrate the distribution across region of
four variables; gender, median age, stage of disease and
frequency of the nine most prevalent diseases in the reg-
istry. The percentage of men per region is 60.2, 56.4, and
66.8 % for Brussels, Flanders and Wallonia, respectively.
The median age is 47 for Brussels and Flanders but of 32 in
Wallonia. In Brussels and Wallonia, almost three quarters
of the patients are symptomatic whereas in Wallonia there
are more than a third that are bound to a wheel-chair.
Table 4 shows the ranking of the nine most prevalent
diseases across regions. We notice variations according to
region as highlighted by the color-codes to guide the
reader.
Table 2 Prevalence of the nine most frequent neuromuscular diseases according to the literature review and the estimated prevalence in
BNMDR per 100,000 inhabitants (BNMDR 2010)
Prevalence
in the literature
Overall prevalence
in Belgium
Prevalence in the north of Belgium Prevalence in the south of Belgium
Frequency Frequency CIa Frequency CIa Frequency CI*
HMSN [18–21] 17.0–41.0 4.2 3.8–4.6 6.5 5.8–7.1 1.3 1.0–1.7
DM1 [22, 23] 1.2–14.3 3.7 3.4–4.1 5.7 5.1–6.3 0.8 0.5–1.1
ALS [24, 25] 5.2–10.3 3.2 2.9–3.6 5.0 4.4–5.5 0.7 0.5–1.1
DMD [19, 26]b 16.7–28.6 4.3 3.8–4.9 5.1 4.4–6.0 0.3 0.3–0.4
LGMD [24, 27] 2.3 1.5 1.2–1.7 2.1 1.8–2.5 0.8 0.5–1.1
HSP [28] 1.6–18.5 1.3 1.1–1.5 2.1 1.7–2.5 1.4 0.5–3.3
SCA [29] 0.3–3.0 1.2 1.0–1.5 2.2 1.8–2.6 0 0
CIDP [30] 0.8–8.9 1.1 0.9–1.3 1.7 1.3–2.0 1.4 0.5–3.3
FSH [19] 10–20 0.9 1.0–1.5 1.2 1.0–1.5 0.5 0.3–0.8
a Confidence interval (CI), Poisson 95 %
b Only in the male population
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Discussion
In this paper, we detailed how the Belgian global Neuro-
muscular Disease Registry was designed, then presented
the most recent data collected, in 2010.
Quality, representativeness and exhaustiveness
of the data
The first goal of the registry is to collect high quality data.
Different mechanisms were implemented during the data
collection of the registry to improve its data quality.
Constant interaction took place between the WIV-ISP and
the data encoders of the NMRCs, minimizing data encod-
ing errors. Drop down menus in the web-application were
instated, to ensure uniform data classification. A unique
BNMDR-id was generated per patient, which allows
identification of each patient, eliminating double entries of
patients visiting more than one centre. This identification
number can also be used in the future for data comparison
and internal validation of the data. Lastly, at the end of
each data collection, a feedback report was sent to each
centre, used as guidance for improvement of future data
collections.
The second goal is that the sample captured in the
registry be representative of the target population. Without
gold standards guiding the test of this hypothesis, the dis-
tribution of four variables was examined. The four tested
variables were gender, median age, stage of disease and
ranking of the most prevalent disease across regions. In
Table 3, differences across regions can be noted, such as a
10 % difference in percentage of males, found in the reg-
istry, between Flanders and Wallonia, or a 15 years dif-
ference in median age between both same regions. The
stages of disease also differ across regions with more
severely diseased patients in Wallonia. The ranking of the
nine most prevalent diseases also differs across regions. As
there is unequal distribution of patient characteristics
across regions, with no valid epidemiological arguments
supporting these findings, we can argue that these differ-
ences are related to poor representativeness of the target
population.
The third goal of the registry is to include the entire
target population. Table 2 charts the estimated prevalence
in the registry in comparison to the values found in similar
8 − 10
11 − 20
21 − 30
31 − 40
41 − 50
51 − 60
61 − 73 NMRCs
Fig. 1 Estimated prevalence of
the nine most prevalent
neuromuscular disease groups
per residential district per
100,000 inhabitants (n = 3,408)
(BNMDR 2010)
Table 3 Gender, median age, stage of disease across region
(BNMDR 2010)
Brussels
(n = 88)
Flanders
(n = 1,813)
Wallonia
(n = 211)
Gender (%)
Males 60.2 56.4 66.8
Age (CI 95 %)
Median 47 (30–50.1) 47 (45–48) 32 (26–38)
Stage of disease (%)
Asymptomatic 0 1.2 1
Ambulatory 77.4 73.7 58.6
Wheel chair 20.2 22.8 35.3
Life support 2.4 2.2 5
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published research. The overall trend is lower values in the
registry, for instance, five times lower for Hereditary Motor
and Sensory Neuropathy and around three times lower for
Myotonic Dystrophy type 1. Some of these differences can
be explained by the wide range of origin of data used to
calculate the prevalence in the literature, originating from
various settings and using different classification systems.
Another aspect which could show the exhaustiveness of the
registry would be to observe the overall estimated preva-
lence of these diseases throughout the country. Figure 1 is
a map representing the estimated prevalence of neuro-
muscular diseases per 100,000 inhabitants. We notice an
under-registration of patients from the south of the country.
Different hypotheses can explain this discrepancy. As a
reminder, registration in the BNMDR only occurs through
the neurologists in the NMRCs. It has been described that
some patients coming to the NMRCs are not being inclu-
ded in the registry due to the burden of encoding on the
neurologists who are seeing many patients but have no time
for administration. Other patients are not coming to the
NMRC, hence, are not being included in the registry.
Hypotheses could be that, first, as neuromuscular diseases
vary in intensity, some asymptomatic patients, or patients
with mild symptoms, might not feel the need to consult a
NMRC on a yearly basis, which are lost in the yearly data
collections. Second, other patients might not come because
there are no NMRCs in their area, especially in the south of
the country. This could mean that patients are either seen
by their general practitioners or in smaller hospitals not
collecting data for the registry. Third, physical disability
could be a barrier to reach the local NMRC. And last, some
patients might not be aware that a registry exists. These
prevalence and distribution discrepancies show that
BNMDR has not reached its potential of having exhaustive
data. For future epidemiological standards, we could
investigate the possibility of expanding and reaching out to
all patients with these diseases in the country.
Strengths and limitations
Although the registry cannot claim at this point to be
optimal, its setup process can be used as a guide for other
countries ready to launch such registries. The transferable
strengths of the registry include the coding, by a third
party, of a unique and fixed BNMDR-identification number
for each patient. This facilitates the consistent identifica-
tion of double entries, thus improving the validity of the
collected data and permitting future longitudinal research.
In addition, this study has adapted the data collecting tool,
shifting from a locally installed ACCESS tool, to an online
web application allowing easier data transfer, data correc-
tion and data collecting.
Another strength is to begin with a minimum set of
variables allowing the encoders to become familiar with
the registry instrument before transforming it to a more
complex instrument, ensuring better data entry. Finally,
working in close collaboration with the partners, enabled
improved data collection and resolving of potential issues
that arose. The Dutch neuromuscular disease registry has
already collected data from more than 10,000 patients in
less than 10 years [9] and New Zealand around 100 after
5 years of careful planning [15]. Hence, Belgium, after
5 years of data collection, with data from 3,424 patients is
within expected progression.
On the other hand, certain limitations influenced the
quality of the data collection, the representativeness of the
registry and its completeness. It is difficult to compare reg-
istries to one another as there is no international consensus as
to which set of diseases should be considered in a neuro-
muscular disease registry, hence no gold standard. The non-
standardised classification of diseases entails subjective
classification and prevents international comparison. The
experts of the BNMDR remodelled the earlier version of
disease classification after the registry was launched, making
comparison with previous data collections impossible. Also,
Table 4 Disease frequency of nine more frequent disease groups across region (BNMDR 2010)
Brussels (n = 88) Flanders (n = 1,813) Wallonia (n = 211)
Disease Frequency Percentage Disease Frequency Percentage Disease Frequency Percentage
2010 DM1 20 22.7 HMSN 404 22.3 DMD 58 27.5
DMD 14 15.9 DM1 359 19.8 HMSN 46 21.8
ALS 13 14.8 ALS 314 17.3 LGMD 27 12.8
FSH 10 11.4 DMD 159 8.8 DM1 27 12.8
HMSN 10 11.4 SCA 135 7.5 ALS 26 12.3
CIDP 10 11.4 LGMD 132 7.3 FSH 17 8.1
HSP 6 6.8 HSP 129 7.1 HSP 5 2.4
LGMD 5 5.7 CIDP 104 5.7 CIDP 5 2.4
SCA 0 0.0 FSH 77 4.3 SCA 0 0.0
88 100 1,813 100 211 100
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the new classification should have mirrored the Orphanet
classification, used in the Belgian central registry for rare
diseases, withwhich it will soonmerge. At last, the estimated
prevalence is calculated on very small patient populations
nationwide which may lead to biases.
Opportunities for further research
The BNMDR has been operating for a few years and is
now ready to expand from a basic set of core data to more
detailed modules. The 2011 and 2012 latest data collection
tool, called version 2, will include two extra modules, a
scale measuring the ability to carry out daily activities
called ACTIVLIM [16], and data collection for potential
clinical trial selection, following the guidance of TREAT-
NMD [17] protocol. ACTIVLIM is a self-administered, 22
closed multiple choice questionnaire that BNMDR patients
are asked to complete on a yearly basis. It is based on
Rasch analysis and can show evolution of disease
throughout time. To simplify and ensure more quality in
the data collection, an eHealth platform service module,
‘‘ConsultRN’’, will be included in the tool. This will enable
the web application to directly retrieve demographic data
from the national registry into the BNMDR registry
improving accuracy. The registry may also benefit from
future efforts to extract diagnostic and treatment data
directly from the patients’ electronic health records, thus
reducing the registration burden on care providers. As the
BNMDR aims to provide a tool to improve health care
quality for patients with neuromuscular diseases, new
variables will be added in the future data collections to
benchmark these trends based on the principle of audit and
feedback. The current feedback focuses mostly on
improving the completeness and data quality of the regis-
tered patients and not clinical performance.
Conclusions
This study shows that BNMDR can be seen as a pacesetter
in guiding other countries to launch a global neuromuscular
disease registry. We have seen how challenging it is to
gather high quality data, for the sample to be representative
and for the registry to be complete. To this day, the true
burden of neuromuscular diseases in Belgium is not
known. The past 5 years of building the registry have
improved its quality, albeit the consistent gap in data from
the south of the country prevents having a clear represen-
tation of the estimated prevalence of these diseases in
Belgium. The results show an unequal planning of
healthcare services for NMD patients in Belgium, an issue
to be brought forward to the Public Health authorities.
Today, patients are being recruited for clinical trials
through the registry. It remains crucial, for comparison, to
emphasise the need of an international classification, for all
neuromuscular diseases such as the one being developed by
the European network Orphanet.
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